Loxo gains after patient responds in LOXO-101 trial

Loxo Oncology Inc. (NASDAQ:LOXO) gained $4.33 (26%) to $20.91 after Cancer Discovery published a brief describing a response in the first patient in a Phase I trial of LOXO-101 in patients with advanced solid tumors.

The brief described one female patient with a tropomyosin receptor kinase fusion cancer, specifically advanced soft tissue sarcoma metastatic to the lungs, who had received multiple prior treatments. Loxo said the patient had a partial response after one month and "almost complete tumor disappearance" after four months of treatment with the neurotrophic tyrosine kinase receptor 1 ( TrkA; NTRK1) inhibitor. Loxo said the patient's shortness of breath was resolved and quality of life improved. ...